Login to Your Account



Genentech, Serono Raptiva Deal Widened To 15 Asian Countries

By Randall Osborne


Friday, February 7, 2003
With a biologics license application pending for the psoriasis drug Raptiva (efalizumab) at the FDA, Genentech Inc. and Serono SA said they are expanding their overseas development and marketing agreement to add 15 Asian companies to an existing deal that covered Europe. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription